231 related articles for article (PubMed ID: 26829221)
1. Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Ouyang M; White EE; Ren H; Guo Q; Zhang I; Gao H; Yanyan S; Chen X; Weng Y; Da Fonseca A; Shah S; Manuel ER; Zhang L; Vonderfecht SL; Alizadeh D; Berlin JM; Badie B
PLoS One; 2016; 11(2):e0148139. PubMed ID: 26829221
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Dai B; Qi N; Li J; Zhang G
Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
[TBL] [Abstract][Full Text] [Related]
3. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
4. Immunostimulatory CpG on Carbon Nanotubes Selectively Inhibits Migration of Brain Tumor Cells.
Alizadeh D; White EE; Sanchez TC; Liu S; Zhang L; Badie B; Berlin JM
Bioconjug Chem; 2018 May; 29(5):1659-1668. PubMed ID: 29526082
[TBL] [Abstract][Full Text] [Related]
5. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
6. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
[TBL] [Abstract][Full Text] [Related]
7. Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Torres S; Tseng J; Leong MN; Lee DJ; Goldkorn A; Xu T; Petasis NA; Louie SG; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2012 Nov; 11(11):2462-72. PubMed ID: 22933703
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
McConville P; Hambardzumyan D; Moody JB; Leopold WR; Kreger AR; Woolliscroft MJ; Rehemtulla A; Ross BD; Holland EC
Clin Cancer Res; 2007 May; 13(10):2897-904. PubMed ID: 17504989
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Albanese C; Alzani R; Amboldi N; Degrassi A; Festuccia C; Fiorentini F; Gravina G; Mercurio C; Pastori W; Brasca M; Pesenti E; Galvani A; Ciomei M
Br J Pharmacol; 2013 May; 169(1):156-66. PubMed ID: 23347136
[TBL] [Abstract][Full Text] [Related]
10. Preparation of immunostimulatory single-walled carbon nanotube/CpG DNA complexes and evaluation of their potential in cancer immunotherapy.
Zhou S; Hashida Y; Kawakami S; Mihara J; Umeyama T; Imahori H; Murakami T; Yamashita F; Hashida M
Int J Pharm; 2014 Aug; 471(1-2):214-23. PubMed ID: 24861942
[TBL] [Abstract][Full Text] [Related]
11. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.
Sun S; Du G; Xue J; Ma J; Ge M; Wang H; Tian J
Int J Immunopathol Pharmacol; 2018; 32():2058738418787991. PubMed ID: 29993291
[TBL] [Abstract][Full Text] [Related]
12. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
Zhu X; Fujita M; Snyder LA; Okada H
J Neurooncol; 2011 Aug; 104(1):83-92. PubMed ID: 21116835
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Asparaginase
Sanghez V; Chen M; Li S; Chou TF; Iacovino M; Lin HJ; Lasky JL; Panosyan EH
Anticancer Res; 2018 May; 38(5):2627-2634. PubMed ID: 29715082
[TBL] [Abstract][Full Text] [Related]
14. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Moroz MA; Huang R; Kochetkov T; Shi W; Thaler H; de Stanchina E; Gamez I; Ryan RP; Blasberg RG
Clin Cancer Res; 2011 May; 17(10):3282-92. PubMed ID: 21385926
[TBL] [Abstract][Full Text] [Related]
15. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity.
Zhao D; Alizadeh D; Zhang L; Liu W; Farrukh O; Manuel E; Diamond DJ; Badie B
Clin Cancer Res; 2011 Feb; 17(4):771-82. PubMed ID: 21088258
[TBL] [Abstract][Full Text] [Related]
16. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
17. Fasting enhances the response of glioma to chemo- and radiotherapy.
Safdie F; Brandhorst S; Wei M; Wang W; Lee C; Hwang S; Conti PS; Chen TC; Longo VD
PLoS One; 2012; 7(9):e44603. PubMed ID: 22984531
[TBL] [Abstract][Full Text] [Related]
18. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide reverses doxorubicin resistance by inhibiting P-glycoprotein in malignant glioma cells.
Zhang R; Saito R; Shibahara I; Sugiyama S; Kanamori M; Sonoda Y; Tominaga T
J Neurooncol; 2016 Jan; 126(2):235-42. PubMed ID: 26530267
[TBL] [Abstract][Full Text] [Related]
20. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Ziegler DS; Keating J; Kesari S; Fast EM; Zawel L; Ramakrishna N; Barnes J; Kieran MW; Veldhuijzen van Zanten SE; Kung AL
Neuro Oncol; 2011 Aug; 13(8):820-9. PubMed ID: 21724651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
